Transparency
What this site is built on
Every factual claim traces to a primary source — an FDA label, a randomized trial, a meta-analysis, or an official agency statement. Here they all are, grouped by how much weight each kind of evidence can bear. We sell you nothing: no sponsors, no affiliates, no ads.
290 unique sources · 10 evidence types · across 52 evidence pages, 22 articles, and 4 brand hubs
How we grade
Every answer carries a rung on the 8-rung Evidence Ladder — strongest (consistent human trials) at the top, theory and danger at the bottom. The source’s type is the first thing that sets the rung: a randomized trial can support a stronger claim than an observational study or an anecdote. Read the full method →
Randomized controlled trials 84
The strongest test of cause and effect — people randomly assigned to drug or placebo.
- Alfaris N, Kushner RF, Li J, et al. Tirzepatide for obesity in adults ≥65 years: post hoc analysis of the SURMOUNT and SUMMIT programs. Diabetes Obes Metab. 2026. doi:10.1111/dom.70991 (weight reduction and adverse-event profile broadly comparable in ≥65 vs <65).dom-pubs.pericles-prod.literatumonline.com ↗
- Ard J, et al. Time course and predictors of weight-loss response with tirzepatide (SURMOUNT-1 post hoc). Diabetes Obes Metab 2025. PMID 40677091. (18% under 5% at week 12; about 90% reached ≥5% by week 72; roughly 1.8% (28/1545) still under 5% at week 72.)pubmed.ncbi.nlm.nih.gov ↗
- Aroda VR et al. PIONEER 1: Oral Semaglutide Monotherapy vs Placebo in Type 2 Diabetes (Diabetes Care 2019;42:1724–1732)pubmed.ncbi.nlm.nih.gov ↗
- Aronne et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5, NEJM 2025)pubmed.ncbi.nlm.nih.gov ↗
- Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (SURMOUNT-4). JAMA. 2024;331(1):38–48.pubmed.ncbi.nlm.nih.gov ↗
- Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4). JAMA. 2024;331(1):38–48.doi.org ↗
- Aronne LJ et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5, NEJM 2025)nejm.org ↗
- Bajaj HS, et al. Efficacy and safety of retatrutide in people with type 2 diabetes (TRANSCEND-T2D-1): a phase 3 trial. The Lancet. 2026. (PMID 42250575)pubmed.ncbi.nlm.nih.gov ↗
- Bliddal H, et al. Semaglutide in obesity and knee osteoarthritis (STEP 9). N Engl J Med. 2024 (n=407, obesity + moderate knee OA, 68 wk): weight −13.7% vs −3.2%; WOMAC pain −41.7 vs −27.5; SF-36 physical function +12.0 vs +6.5 (all P<0.001). Summarized via NEJM press release.prnewswire.com ↗
- Blundell J, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017;19(9):1242–1251. (−24% total ad-lib energy intake at 12 weeks; less hunger, better control of eating. Gastric-emptying data reported separately — see Hjerpsted 2018.)pmc.ncbi.nlm.nih.gov ↗
- Bone-mineral density and bone-turnover response to GLP-1 receptor agonist in older adults: 20-week pilot post hoc analysis (n=20, mean age 72.7). No significant between-group whole-body BMD difference (p=0.77); CTX p=0.56, P1NP p=0.78; non-significant adverse trend; underpowered. PMC12695752.pmc.ncbi.nlm.nih.gov ↗
- Buse JB, et al. Cagrilintide–semaglutide versus semaglutide 2.4 mg in type 2 diabetes (REIMAGINE 2), peer-reviewed head-to-head. Lancet Diabetes & Endocrinology. 2026. (presented ADA 2026)thelancet.com ↗
- Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes (SURPASS-CVOT). N Engl J Med. 2025;393:2409–2420.nejm.org ↗
- Davies MJ, et al. Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes (REDEFINE 2). N Engl J Med. 2025;393(7):648–659. DOI 10.1056/NEJMoa2502082.nejm.org ↗
- Deanfield J, Lincoff AM, Kahn SE, et al. Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial. Lancet 2025 (published online Oct 22, 2025). (About 33% of the MACE benefit mediated by waist-circumference change; no linear trend of week-20 weight loss with subsequent MACE; benefit consistent across baseline weight/waist categories.)thelancet.com ↗
- Effect of Semaglutide on Regression and Progression of Glycemia in People with Overweight or Obesity without Diabetes (SELECT). Diabetes Care 2024. (Progression to diabetes HR 0.27, 95% CI 0.24–0.31, a 73% reduction; cumulative incidence 1.5% vs 6.9% at 156 wk; regression to normoglycemia 69.5% vs 35.8%; 34.5% of the diabetes-prevention effect mediated by weight; mean weight loss 9.74% vs 0.85%.)pmc.ncbi.nlm.nih.gov ↗
- ESSENCE — Sanyal AJ, et al. Semaglutide in MASH (72-week interim). NEJM 2025 (MASH resolution 62.9% vs 34.3%; fibrosis improvement 36.8% vs 22.4%).prnewswire.com ↗
- evoke / evoke+ (oral semaglutide in early Alzheimer's disease) — Novo Nordisk phase 3 topline announcement, November 24, 2025 (n=3,808; no significant CDR-SB benefit at week 104; biomarkers moved but did not translate to clinical benefit).biospace.com ↗
- Exenatide-PD3 — Vijiaratnam N, et al. Exenatide once weekly in Parkinson's disease. Lancet 2025 (phase 3, n=194, 96 weeks; no evidence of slowed progression).thelancet.com ↗
- Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2, NEJM 2021)nejm.org ↗
- Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, phase 3 trial. Lancet. 2023;402:613–626.pubmed.ncbi.nlm.nih.gov ↗
- Garvey WT, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1). N Engl J Med. 2025;393(7):635–647. DOI 10.1056/NEJMoa2502081.nejm.org ↗
- Garvey WT, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022. (Mean weight −15.2% vs −2.6% placebo at week 104; plateau ~week 60; −15.6% at week 52 held to −15.2% at week 104; n=304.)pmc.ncbi.nlm.nih.gov ↗
- Hansen MSS, et al. Once-weekly semaglutide versus placebo in adults with increased fracture risk: a randomised, double-blinded, phase 2 trial. eClinicalMedicine. 2024;72:102624. (N=64, 55 postmenopausal women; modest hip/spine BMD drop 'may be explained by the accompanying weight loss.')pubmed.ncbi.nlm.nih.gov ↗
- Hendershot CS et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2025;82(4):395–405.pubmed.ncbi.nlm.nih.gov ↗
- Hendershot CS, et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry 2025;82(4):395–405 (phase 2, n=48; heavy drinking β 0.84, p=0.04; craving β −0.39, p=0.01; drinks/day β −0.41, p=0.04).jamanetwork.com ↗
- Hjerpsted JB, et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes Obes Metab. 2018;20(3):610–619. (Same trial as Blundell 2017; gastric emptying delayed in the first postprandial hour, with overall gastric emptying not significantly different from placebo.)pmc.ncbi.nlm.nih.gov ↗
- Horn DB, Kahan S, Batterham RL, et al. Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials. Clinical Obesity. 2025;15(3):e12734. (Median time to plateau 24.3 weeks (overweight) to 36.1 weeks (class III obesity); higher dose delayed plateau by +4.4 and +6.7 weeks; ~88–90% plateaued by week 72, ~12% had not.)pmc.ncbi.nlm.nih.gov ↗
- Horn et al. Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials (Clinical Obesity 2025)pubmed.ncbi.nlm.nih.gov ↗
- Husain M et al. Oral Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes (PIONEER 6, NEJM 2019;381:841–851)nejm.org ↗
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1, NEJM 2022)nejm.org ↗
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387:205–216.doi.org ↗
- Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389:514–526.doi.org ↗
- Jastreboff et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1, NEJM 2022)pubmed.ncbi.nlm.nih.gov ↗
- Jastreboff et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial (NEJM 2023)pubmed.ncbi.nlm.nih.gov ↗
- Jensen SBK et al. Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis. eClinicalMedicine. 2024;69:102475.doi.org ↗
- Kapitza C et al. Semaglutide Does Not Reduce the Bioavailability of a Combined Oral Contraceptive (J Clin Pharmacol 2015;55:497–504)pmc.ncbi.nlm.nih.gov ↗
- Kapitza C, et al. Semaglutide does not reduce the bioavailability of the combined oral contraceptive ethinylestradiol/levonorgestrel. J Clin Pharmacol. 2015. PMID 25475122.pubmed.ncbi.nlm.nih.gov ↗
- Knop FK et al. Oral semaglutide 50 mg in adults with overweight or obesity (OASIS 1, Lancet 2023;402:705–719)thelancet.com ↗
- Kosiborod MN, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (STEP-HFpEF). NEJM 2023. (KCCQ-CSS symptom score placebo-adjusted +7.8, 95% CI 4.8–10.9.)nejm.org ↗
- Lau DCW, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a phase 2 dose-finding trial. The Lancet. 2021;398(10317):2160–2172.thelancet.com ↗
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389:2221–2232.doi.org ↗
- Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). NEJM 2023. ACC summary. (MACE HR 0.80, 95% CI 0.72–0.90; 6.5% vs 8.0%; n=17,604; overweight/obese with established CVD, no diabetes; semaglutide 2.4 mg.)acc.org ↗
- Lincoff et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT, NEJM 2023)nejm.org ↗
- LIXIPARK — Meissner WG, et al. Lixisenatide in Early Parkinson's Disease. NEJM 2024 (phase 2; small, marginal signal of slowed motor progression). DOI: 10.1056/NEJMoa2312323.nejm.org ↗
- Look et al. Tirzepatide and body composition: DXA substudy of SURMOUNT-1 (Diabetes Obes Metab, 2025)pmc.ncbi.nlm.nih.gov ↗
- Loomba R et al. Tirzepatide for MASH with Liver Fibrosis (SYNERGY-NASH, NEJM 2024;391:299–310)nejm.org ↗
- Lundgren JR et al. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. N Engl J Med. 2021;384:1719–1730.doi.org ↗
- Malhotra A et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA, NEJM 2024;391:1193–1205)pmc.ncbi.nlm.nih.gov ↗
- Malhotra A, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea (SURMOUNT-OSA). NEJM 2024. (AHI change −25.3 vs −5.3/hr without PAP; −29.3 vs −5.5/hr with PAP; 52 wk.)nejm.org ↗
- Marso et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6, NEJM 2016)pubmed.ncbi.nlm.nih.gov ↗
- Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6; retinopathy signal). N Engl J Med. 2016.nejm.org ↗
- McGuire DK et al. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes (SOUL, NEJM 2025)nejm.org ↗
- OASIS 1 (oral semaglutide 50 mg, investigational). Lancet, 2023 (PMID 37385278) — −15.1% vs placebo −2.4% at 68 weeks.pubmed.ncbi.nlm.nih.gov ↗
- OASIS 4 (oral semaglutide 25 mg, "oral Wegovy") — ACC journal scan, 2025: −16.6% (efficacy) / −13.6% (treatment-regimen) vs ~−2.7% placebo at 64 weeks.acc.org ↗
- Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial. The Lancet. 2026.thelancet.com ↗
- Orforglipron for obesity in people with type 2 diabetes (ATTAIN-2, The Lancet 2025)doi.org ↗
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1, phase 3). N Engl J Med. 2025;393:1796–1806. DOI 10.1056/NEJMoa2511774.doi.org ↗
- Perkovic V, et al. Effects of Semaglutide on Chronic Kidney Disease in Type 2 Diabetes (FLOW). NEJM 2024. (Kidney composite HR 0.76, 95% CI 0.66–0.88, a 24% relative reduction.)nejm.org ↗
- Rubino D et al. Effect of Continued Weekly Semaglutide vs Placebo on Weight-Loss Maintenance (STEP 4). JAMA. 2021;325(14):1414–1425.doi.org ↗
- Rubino D, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance: The STEP 4 Randomized Clinical Trial. JAMA. 2021. (After a 20-week run-in, switch to placebo regained 6.9% over 48 weeks vs a further 7.9% loss on semaglutide; net −5.0% vs −17.4% from baseline.)jamanetwork.com ↗
- Rubino D, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance: The STEP 4 Randomized Clinical Trial. JAMA. 2021. (Continued-semaglutide arm lost a further 7.9% from week 20 to 68; placebo-switchers regained.)pmc.ncbi.nlm.nih.gov ↗
- Rubino et al. Continued vs Withdrawn Semaglutide on Weight-Loss Maintenance (STEP 4, JAMA 2021)pubmed.ncbi.nlm.nih.gov ↗
- Sanyal AJ, Newsome PN et al. Phase 3 Trial of Semaglutide in MASH (ESSENCE, NEJM 2025;392:2089–2099)pubmed.ncbi.nlm.nih.gov ↗
- SELECT trial (semaglutide, cardiovascular outcomes): n=17,604, mean age 61.6, established cardiovascular disease without diabetes; 20% reduction in major adverse cardiovascular events, consistent across age subgroups. PMC11271387.pmc.ncbi.nlm.nih.gov ↗
- STEP 1 body-composition analysis — semaglutide effects on lean and fat mass (DXA substudy)pmc.ncbi.nlm.nih.gov ↗
- STEP-HFpEF program: effects across the age spectrum (n=1,145; 25.5% aged ≥75; median age 69). KCCQ symptom, 6-minute-walk and weight benefits preserved across age; in the ≥75 group the placebo-adjusted between-group differences were +5.6 KCCQ points (p-interaction 0.80), +16.3 m walk (p-interaction 0.96), and −7.7% weight (semaglutide −11.5% vs placebo −3.8%; p-interaction 0.41). PMC12765414.pmc.ncbi.nlm.nih.gov ↗
- Tchang BG, et al. Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the SURMOUNT program. Obesity (Silver Spring). 2025;33(5):851–860. (2,542 women; ~26% premenopause / ~23% peri / ~23% postmenopause at 72 wk; efficacy 'irrespective of reproductive stage.')pubmed.ncbi.nlm.nih.gov ↗
- van Bloemendaal et al. GLP-1 Receptor Activation Modulates Appetite- and Reward-Related Brain Areas in Humans (Diabetes 2014)pubmed.ncbi.nlm.nih.gov ↗
- Villareal DT et al. Aerobic or Resistance Exercise, or Both, in Dieting Obese Older Adults. N Engl J Med. 2017;376:1943–1955.doi.org ↗
- Wadden TA et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3). Nat Med. 2023;29:2909–2918.nature.com ↗
- Wharton S, Lingvay I, Bogdanski P et al. Oral Semaglutide 25 mg in Adults with Overweight or Obesity (OASIS 4, NEJM 2025)nejm.org ↗
- Wharton, Aronne et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1, NEJM 2025;393:1796-1806)nejm.org ↗
- Wilding et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1, NEJM 2021)pubmed.ncbi.nlm.nih.gov ↗
- Wilding et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1, NEJM 2021)nejm.org ↗
- Wilding et al. Weight Regain and Cardiometabolic Effects After Withdrawal of Semaglutide (STEP 1 extension, Diabetes Obes Metab 2022)pmc.ncbi.nlm.nih.gov ↗
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1, NEJM 2021)nejm.org ↗
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989–1002.doi.org ↗
- Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: STEP 1 extension. Diabetes Obes Metab. 2022;24(8):1553–1564.doi.org ↗
- Wilding JPH, et al. Body composition changes with semaglutide (STEP 1 DXA substudy). J Endocr Soc 2021 (Endocrine Society abstract). (~60% fat / ~40% lean; total fat −19.3%; visceral fat −27.4%.)academic.oup.com ↗
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989-1002. Categorical responder rates (≥5% 86.4%, ≥10% 69.1%, ≥15% 50.5%; placebo 31.5% / 12.0% / 4.9%) via WikiJournalClub summary of the trial.wikijournalclub.org ↗
- Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24:1553–1564. (Completers regained about two-thirds of lost weight within a year of stopping.)ncbi.nlm.nih.gov ↗
- Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022.dom-pubs.onlinelibrary.wiley.com ↗
- Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022. (Mean 17.3% loss at week 68; +11.6 percentage points regained by week 120 — about two-thirds of the loss; net −5.6% vs −0.1% placebo; ≥5% loss maintained fell from 86.4% to 48.2%.)pubmed.ncbi.nlm.nih.gov ↗
Meta-analyses 29
Pooled results across many trials.
- Aquatic exercise in older adults — meta-analysis of 19 RCTs (866 participants): improved lower-limb strength, flexibility, and mobilitypmc.ncbi.nlm.nih.gov ↗
- Body-composition network meta-analysis of GLP-1 receptor agonists and co-agonists (lean mass ≈ 25% of total weight lost, −0.86 kg of −3.55 kg; relative lean percentage unchanged). PubMed PMID 39719170.pubmed.ncbi.nlm.nih.gov ↗
- Castagna et al. Apple cider vinegar on body composition: systematic review and meta-analysis of RCTs. Nutrients. 2025 (10 RCTs, 789 participants, mostly adults with overweight and/or type 2 diabetes). (Body weight SMD −0.39; BMI SMD −0.65; high heterogeneity and publication-bias caveats; 4–12-week trials.)pmc.ncbi.nlm.nih.gov ↗
- Chair-based resistance-band exercise in long-term-care older adults — meta-analysis of 9 RCTs (878 participants, many wheelchair/walking-aid users): improved handgrip strength and upper/lower-limb muscle endurancepmc.ncbi.nlm.nih.gov ↗
- Darooghegi Mofrad M, et al. Effect of psyllium fibre on body weight, BMI and waist: dose-response meta-analysis of 22 RCTs. Crit Rev Food Sci Nutr. 2020. (No significant independent effect on body weight.)tandfonline.com ↗
- Effects of glucagon-like peptide-1 receptor agonists on alcohol consumption: a systematic review and meta-analysis. eClinicalMedicine. 2025. (doi:10.1016/j.eclinm.2025.103645)pmc.ncbi.nlm.nih.gov ↗
- Elkin R, et al. Association between glucagon-like peptide-1 receptor agonist use and peri-operative pulmonary aspiration: a systematic review and meta-analysis. Anaesthesia. 2025. (PMID 40230298)pubmed.ncbi.nlm.nih.gov ↗
- Enhanced protein intake on maintaining muscle mass, strength, and physical function in adults with overweight/obesity: a systematic review and meta-analysis. Clin Nutr ESPEN. 2024;62:135–146.doi.org ↗
- Forslund M, et al. GLP-1 receptor agonist treatment in women with polycystic ovary syndrome: a systematic review and meta-analysis. Eur J Endocrinol. 2026;194(3):S25–S39. (11 RCTs; modest weight loss, low-certainty; no significant HOMA-IR change; reproductive benefits uncertain.)doi.org ↗
- Gibb RD, Sloan KJ, McRorie JW. Psyllium is a gel-forming fiber effective for weight loss: review and meta-analysis. J Am Assoc Nurse Pract. 2023 (6 RCTs, 354 participants; −2.1 kg). NOTE: all three authors are employees of Procter & Gamble, maker of a psyllium fiber brand — a conflict of interest disclosed here.pmc.ncbi.nlm.nih.gov ↗
- He L, et al. Association of GLP-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: Meta-analysis of Randomized Clinical Trials. JAMA Intern Med. 2022.jamanetwork.com ↗
- Ho J, et al. Glucagon-Like Peptide-1 Receptor Agonists and Peri-Procedural Aspiration Risk. J Endocr Soc. 2025. (PMID 40893948)pubmed.ncbi.nlm.nih.gov ↗
- Kim JE, et al. Effects of dietary protein intake on body composition changes after weight loss in older adults — meta-analysis of 20 RCTs (adults 50+): higher-protein groups lost ~0.45–0.83 kg less lean mass and more fat; ≥30% of weight lost was lean tissue in ~22% of higher-protein vs ~48% of normal-protein comparisonspmc.ncbi.nlm.nih.gov ↗
- Liu Y, et al. Berberine on components of metabolic syndrome: meta-analysis of placebo-controlled RCTs. Front Pharmacol. 2025. (Waist −3.27 cm; BMI −0.435 kg/m²; authors call for higher-quality trials.)pubmed.ncbi.nlm.nih.gov ↗
- López P, et al. Resistance training and body composition across the lifespan — systematic review and meta-analysis (Obesity Reviews, 2022)onlinelibrary.wiley.com ↗
- Morton et al. Protein supplementation and resistance-training gains in muscle mass and strength: a systematic review and meta-analysis (Br J Sports Med, 2018)doi.org ↗
- Onakpoya I, Posadzki P, Ernst E. Glucomannan for weight loss: systematic review and meta-analysis of RCTs. 2014. (Body weight −0.22 kg, not statistically significant; no significant weight loss overall.)ncbi.nlm.nih.gov ↗
- Peterson MD, et al. Resistance exercise for muscular strength and lean body mass in aging adults — meta-analysis: pooled lean-mass change ≈ +1.1 kg (95% CI 0.9–1.2); older adults gained less per unit of trainingpmc.ncbi.nlm.nih.gov ↗
- Picos A, Badea ME, Dumitrascu DL. Dental erosion in gastro-esophageal reflux disease. A systematic review. Clujul Med. 2018;91(4):387–390. (Dental erosion 48.81% in GERD vs 20.48% in controls; 10 studies / 7,289 patients — reflux population, not GLP-1 users.)pmc.ncbi.nlm.nih.gov ↗
- Pooled safety of semaglutide in adults ≥65 (PIONEER/SUSTAIN/STEP): STEP ≥65 pool AE 92.4% vs 88.0% placebo, serious AE 15.6% vs 14.3%, GI 73.8% vs 48.6%; discontinuation for adverse events higher in ≥65. PMC12056300.pmc.ncbi.nlm.nih.gov ↗
- Reassessing cancer risk with GLP-1 receptor agonists: a comprehensive meta-analysis of gastrointestinal malignancies. Front Pharmacol. 2026. PMC12929497. (93 RCTs, ~1.85M; pancreatic HR 0.78 [0.61–0.95], colorectal 0.81 [0.68–0.96], liver 0.74 [0.62–0.88]; hypothesis-generating.)pmc.ncbi.nlm.nih.gov ↗
- Sherrington C et al. Exercise for preventing falls in older people living in the community. Cochrane Database Syst Rev. 2019;1:CD012424.doi.org ↗
- Silverii GA, et al. GLP-1 receptor agonists and risk of thyroid cancer: a systematic review and meta-analysis of RCTs. Diabetes Obes Metab. 2024 (PMID 38018310). (MH-OR 1.52, 95% CI 1.01–2.29, P=0.04; 64 trials retrieved, 26 reporting ≥1 thyroid-cancer case; fragility index = 1.)pubmed.ncbi.nlm.nih.gov ↗
- Silverii GA, et al. GLP-1 receptor agonists and the risk for cancer: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2025. PMC12232360. (50 RCTs; overall cancer OR 1.05 [0.98–1.13] NS; colorectal OR 1.27 [1.03–1.57] in shorter trials, attributed to detection.)pmc.ncbi.nlm.nih.gov ↗
- Weidlinger S, et al. Impact of estrogens on resting energy expenditure: A systematic review. Obesity Reviews. 2023;24(10):e13605. (Estrogen raised resting energy expenditure by up to ~200+ kcal/day.)pubmed.ncbi.nlm.nih.gov ↗
- Wycherley et al. Energy-restricted high-protein vs standard-protein diets: a meta-analysis of RCTs (Am J Clin Nutr, 2012)pubmed.ncbi.nlm.nih.gov ↗
- Xiong P, et al. Effects of berberine on obesity indices: systematic review and meta-analysis of 10 RCTs. Complement Ther Clin Pract. 2020. (BMI −0.29 kg/m²; waist −2.75 cm; body weight −0.11 kg, not significant.)pubmed.ncbi.nlm.nih.gov ↗
- Zhang Y, et al. Association of GLP-1 receptor agonists use with fracture risk in type 2 diabetes: A meta-analysis of randomized controlled trials. Bone. 2025;192:117338. (44 RCTs, 47,823 patients; fracture RR 0.77, 95% CI 0.61–0.96.)pubmed.ncbi.nlm.nih.gov ↗
- Zhou L, Qu H, Yang L, Shou L. Effects of GLP-1RAs on pregnancy rate and menstrual cyclicity in women with polycystic ovary syndrome: a meta-analysis and systematic review. BMC Endocr Disord. 2023;23:245. PMC10631119. (11 RCTs / 840 women; natural pregnancy RR 1.72, 95% CI 1.22–2.43; improved menstrual regularity; significant HOMA-IR improvement; no IVF benefit.)doi.org ↗
FDA labels 10
The regulator-approved prescribing information — the authority for approved uses and reported rates.
- Drugs@FDA: Ozempic (semaglutide) approval record (NDA 209637)accessdata.fda.gov ↗
- FOUNDAYO (orforglipron) — DailyMed labeldailymed.nlm.nih.gov ↗
- FOUNDAYO (orforglipron) tablets — FDA Prescribing Information (2026)accessdata.fda.gov ↗
- MOUNJARO (tirzepatide) injection — FDA Prescribing Informationdailymed.nlm.nih.gov ↗
- OZEMPIC (semaglutide) injection — FDA Prescribing Informationdailymed.nlm.nih.gov ↗
- RYBELSUS (oral semaglutide) — FDA Prescribing Information (DailyMed): take on an empty stomach, with no more than 4 oz (120 mL) of plain water, at least 30 minutes before food/drink/other oral medications; swallow whole. Approved 2017, type 2 diabetes.dailymed.nlm.nih.gov ↗
- RYBELSUS / OZEMPIC (oral semaglutide) tablets — FDA Prescribing Information (DailyMed)dailymed.nlm.nih.gov ↗
- WEGOVY (semaglutide) injection — FDA Prescribing Informationdailymed.nlm.nih.gov ↗
- WEGOVY (semaglutide) Prescribing Information — Adverse Reactions and Warnings (DailyMed/FDA label)dailymed.nlm.nih.gov ↗
- ZEPBOUND (tirzepatide) injection — FDA Prescribing Informationdailymed.nlm.nih.gov ↗
Guidelines 30
Consensus recommendations from professional bodies.
- American Dental Association — Dental Erosion (Oral Health Topics): enamel irreversibility, acid-softening, rinse-before-brushing guidance, saliva's role in remineralizationada.org ↗
- American Medical Association. Resolution 420 (A-13): Recognition of Obesity as a Disease. 2013.media.npr.org ↗
- ASA / Multi-society clinical practice guidance for the safe perioperative use of GLP-1 receptor agonists (Oct 2024).asahq.org ↗
- Bray GA, et al. Obesity: a chronic relapsing progressive disease process — a position statement of the World Obesity Federation. Obes Rev. 2017;18(7):715–723.onlinelibrary.wiley.com ↗
- CMS — Medicare GLP-1 Bridge (temporary demonstration program page)cms.gov ↗
- CMS — Prescription Drug Appeals: Exceptions. (Part D formulary/tiering exception: standard decisions within 72 hours, expedited within 24 hours, with a prescriber supporting statement; further internal appeal and external review.)cms.gov ↗
- CMS — Selected Drugs and Negotiated Prices (Medicare Drug Price Negotiation Program)cms.gov ↗
- Cruz-Jentoft et al. Sarcopenia: revised European consensus on definition and diagnosis (EWGSOP2, Age and Ageing, 2019)doi.org ↗
- Declaratory Order: Resolution of Shortages of Semaglutide Injection Products (FDA)fda.gov ↗
- Declaratory Order: Resolution of Shortages of Tirzepatide Injection Products (FDA)fda.gov ↗
- European Medicines Agency — Meeting highlights, Pharmacovigilance Risk Assessment Committee (PRAC), 8–11 April 2024 (review found no causal association between GLP-1 receptor agonists and suicidal/self-injurious thoughts)ema.europa.eu ↗
- FDA — Information for Consumers on Using Dietary Supplements. (Under DSHEA, 1994, the FDA does not approve dietary supplements for safety or effectiveness before they are marketed; manufacturers are responsible for safety and truthful labeling.)fda.gov ↗
- FDA clarifies policies for compounders as national GLP-1 supply begins to stabilizefda.gov ↗
- FDA Drug Safety Communication — Update on FDA's evaluation of reports of suicidal thoughts or actions with GLP-1 RAs (Jan 2024).fda.gov ↗
- FTC — Health Products Compliance Guidance. (Advertising claims must be supported by "competent and reliable scientific evidence.")ftc.gov ↗
- Gorgojo-Martínez JJ, et al. Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with GLP-1 Receptor Agonists: A Multidisciplinary Expert Consensus. J Clin Med. 2022.pmc.ncbi.nlm.nih.gov ↗
- GRADE Working Group — grading quality of evidence and strength of recommendationsgradeworkinggroup.org ↗
- Joshi GP, et al. American Society of Anesthesiologists (ASA) Consensus-Based Guidance on Preoperative Management of Patients on GLP-1 Receptor Agonists. Anesthesiology. 2024;140(2):346.pubs.asahq.org ↗
- Kindel TL, et al. Multisociety Clinical Practice Guidance for the Safe Use of GLP-1 Receptor Agonists in the Perioperative Period (AGA/ASMBS/ISPCOP/SAGES; ASA-affirmed). Surg Endosc. 2024.pmc.ncbi.nlm.nih.gov ↗
- List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B (Federal Register, May 1 2026)federalregister.gov ↗
- List of Bulk Drug Substances Under Section 503B — Extension of Comment Period (Federal Register, Jun 26 2026)federalregister.gov ↗
- Low blood sugar (hypoglycaemia) — NHS (general first-aid: ~15–20 g fast-acting carbohydrate, re-check after 10–15 minutes)nhs.uk ↗
- NIH Office of Dietary Supplements — Biotin: Fact Sheet for Health Professionals. High-dose biotin supplements can cause clinically significant incorrect lab results, including falsely lowered troponin and interference with thyroid assays (a documented immunoassay interference).ods.od.nih.gov ↗
- Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory (ACLM, ASN, OMA, TOS) — PubMed 2025pubmed.ncbi.nlm.nih.gov ↗
- Obesity Medicine Association et al. — Joint Statement to Patients on Compounded GLP-1 Alternativesobesitymedicine.org ↗
- Piercy KL et al. The Physical Activity Guidelines for Americans. JAMA. 2018;320(19):2020–2028.doi.org ↗
- Rinella ME et al. Multisociety Delphi consensus on new fatty liver disease nomenclature (J Hepatol 2023)pubmed.ncbi.nlm.nih.gov ↗
- Rubino F, Cummings DE, Eckel RH, et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes & Endocrinology. 2025;13(3):221-262. PMID 39824205. (Clinical obesity defined as a chronic systemic disease; endorsed by 76 organizations.)pubmed.ncbi.nlm.nih.gov ↗
- TSA — What Can I Bring: Gel Ice Packstsa.gov ↗
- TSA — What Can I Bring: Medications & Medically Necessary Liquidstsa.gov ↗
Reviews 44
Expert syntheses of a body of evidence.
- Alabduljabbar K, et al. Response to GLP-1 receptor agonists: a review of variability. Front Endocrinol 2024;15:1382814. (Low-responders <5%: 10.2–16.7%; super-responders >20%: 32–39.6% across the STEP program.)frontiersin.org ↗
- Alopecia as an Emerging Adverse Effect Associated With GLP-1 Receptor Agonists for Weight Loss: A Scoping Review (Cureus 2025)pmc.ncbi.nlm.nih.gov ↗
- ASPE (HHS) — Medicare Coverage of Anti-Obesity Medicationsaspe.hhs.gov ↗
- Barać M, Roganović J. GLP-1 Receptor Signaling and Oral Dysfunction: A Narrative Review on the Mechanistic Basis of Semaglutide-Related Oral Adverse Effects. Biology (Basel). 2025;14(12):1650. (Mechanistic hypothesis only; 'no direct experimental confirmation of GLP-1R function in human salivary glands.')pmc.ncbi.nlm.nih.gov ↗
- Bariatric Surgery-Induced Telogen Effluvium (Bar SITE): Case Report and Review (Cureus). Telogen effluvium after rapid weight loss — acute onset within the first ~3 months, reversible with "near-complete hair growth" by ~14 months; multifactorial, including protein, iron, and zinc adequacy. PMC8144077.pmc.ncbi.nlm.nih.gov ↗
- Calvarysky B et al. Drug-Drug Interactions Between GLP-1 Receptor Agonists and Oral Medications: A Systematic Review (Drug Safety 2024;47:439–451)pmc.ncbi.nlm.nih.gov ↗
- Chao AM, et al. Clinical Insight on Semaglutide for Chronic Weight Management: Patient Selection and Special Considerations. Drug Des Devel Ther. 2022;16:4449-4461. PMC9807016. Supports the CMS <5%-at-12-weeks non-responder definition, STEP 1 7.6% and STEP 2 26.8% below 5%, and higher non-response in type 2 diabetes.pmc.ncbi.nlm.nih.gov ↗
- Daneshgaran G, Shauly O, Gould DJ. 'Ozempic Face' in Plastic Surgery: A Systematic Review of the Literature on GLP-1 Receptor Agonist Mediated Weight Loss and Analysis of Public Perceptions. Aesthet Surg J Open Forum. 2025;7:ojaf056. (23 articles; concludes GLP-1s 'merely emphasize the age-related gradual decrease in elastin turnover…rather than preferentially resulting in targeted facial fat atrophy'; most included evidence is low-quality opinion/case series.)pmc.ncbi.nlm.nih.gov ↗
- Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metabolism. 2018;27(4):740–756.doi.org ↗
- Egan AG, et al. Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment. N Engl J Med. 2014;370:794–797. (Joint review of 250+ toxicology studies; causal pancreatitis/pancreatic-cancer claims 'inconsistent with the current data.')nejm.org ↗
- From needles to pills: oral GLP-1 therapy enters the obesity arena (review). PMC12498447 — cross-trial responder rates and explicit caution that the absence of a direct comparison makes such judgments premature.pmc.ncbi.nlm.nih.gov ↗
- GI Adverse Effects of Glucagon-Like Peptide-1 Receptor Agonists — U.S. Pharmacistuspharmacist.com ↗
- GLP-1 receptor agonist use in pregnancy — review documenting restored ovulation and unplanned pregnancies (PMID 39181497)pubmed.ncbi.nlm.nih.gov ↗
- GLP-1 receptor agonists and cancer: current clinical evidence and translational opportunities for preclinical research. J Clin Invest. 2025. PMC12578377. (Mechanistic rationale — weight-dependent and weight-independent; detection bias, reverse causation, comparator-confounding limitations.)jci.org ↗
- GLP-1 receptor agonists and sarcopenia / lean-mass loss — narrative review (Diabetes Research and Clinical Practice, 2025): lean mass ~15–40% of weight lost across analyses; clinical significance debated, a greater concern in higher-risk subgroupsdiabetesresearchclinicalpractice.com ↗
- GLP-1 Receptor Agonists for obesity: weight-loss outcomes, tolerability, side effects, and risks (review of GI adverse effects). PMC11404059.pmc.ncbi.nlm.nih.gov ↗
- Guyatt et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations (BMJ, 2008)bmj.com ↗
- Hair Loss Associated With GLP-1 Receptor Agonist Use: A Systematic Review (5 studies, 2,905 patients). Reports SURMOUNT-1 alopecia of 5.1%/5.3%/4.9% at 5/10/15 mg tirzepatide vs 0.9% placebo; mixed findings, some studies reporting regrowth; describes telogen effluvium and androgenetic alopecia patterns. PMC12530271.pmc.ncbi.nlm.nih.gov ↗
- Han J, Lin H, Huang W. Modulating gut microbiota as an anti-diabetic mechanism of berberine. Med Sci Monit. 2011. (A gut-microbiota mechanism hypothesis paper — preclinical; proposes, does not prove, the pathway.)pmc.ncbi.nlm.nih.gov ↗
- Hayashi D, et al. What Is Food Noise? A Conceptual Model of Food Cue Reactivity. Nutrients. 2023;15(22):4809.pubmed.ncbi.nlm.nih.gov ↗
- Hayashi et al. What Is Food Noise? A Conceptual Model of Food Cue Reactivity (Nutrients 2023)pmc.ncbi.nlm.nih.gov ↗
- HHS Office of Inspector General — Manufacturer Safeguards May Not Prevent Copayment Coupon Use for Part D Drugs (OEI-05-12-00540)oig.hhs.gov ↗
- Jain AB et al. Switching between GLP-1 receptor agonists in clinical practice: Expert consensus and practical guidance (Int J Clin Pract 2021)pmc.ncbi.nlm.nih.gov ↗
- Jalleh RJ, et al. Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide. J Clin Endocrinol Metab. 2025.academic.oup.com ↗
- Kennedy C et al. Cardiometabolic risk factors efficacy of semaglutide in the STEP program. Postgrad Med. 2022.pubmed.ncbi.nlm.nih.gov ↗
- KFF — Key Facts About Medicare Drug Price Negotiationkff.org ↗
- KFF — Medicare Advantage prior authorization in 2024 (11.5% of denials appealed; 80.7% overturned).kff.org ↗
- KFF — New OIG Report Examines Prior Authorization Denials in Medicaid MCOs (about one-third of appealed Medicaid managed-care denials overturned)kff.org ↗
- KFF — What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridgekff.org ↗
- Kodoth V, Scaccia S, Aggarwal B. Adverse Changes in Body Composition During the Menopausal Transition and Relation to Cardiovascular Risk: A Contemporary Review. Women's Health Reports. 2022;3(1):573–581. (Visceral fat ~5–8% → ~15–20% of body fat; redistribution tracks estrogen, total gain tracks aging.)pubmed.ncbi.nlm.nih.gov ↗
- Memorial Sloan Kettering Cancer Center — About Herbs: Berberine (professional monograph). (Berberine may reduce activity of CYP2D6, 2C9, and 3A4 substrate drugs; may interact with sulfonylurea diabetes drugs; should be avoided in pregnancy and breastfeeding as it may worsen infant jaundice or cause kernicterus from high bilirubin.)mskcc.org ↗
- Müller MJ, Enderle J, Bosy-Westphal A. Changes in Energy Expenditure with Weight Gain and Weight Loss in Humans. Curr Obes Rep. 2016;5(4):413–423. (Adaptive thermogenesis ~50–140 kcal/day after ~10% loss; individualized trait.)pmc.ncbi.nlm.nih.gov ↗
- Narrative review — GLP-1 receptor agonists for obesity in older women, preserving lean mass (higher baseline sarcopenia risk, anabolic resistance). Nutrients. 2026;18(4):632.mdpi.com ↗
- Periodontitis and GLP-1 pathways: a new frontier in oral-systemic health connections — a scoping review. Front Clin Diabetes Healthc. 2025. PMCID: PMC12643841. (Preclinical/mechanistic frontier; bidirectional periodontitis–GLP-1 links in animal models; explicitly non-causal.)pmc.ncbi.nlm.nih.gov ↗
- Persson C, Eaton A, Mayrovitz HN. A Closer Look at the Dermatological Profile of GLP-1 Agonists. Diseases. 2025;13(5):127. doi:10.3390/diseases13050127 ('the medication promotes systemic fat reduction rather than directly affecting facial fat cells.')pmc.ncbi.nlm.nih.gov ↗
- Phelan SM, et al. Impact of weight bias and stigma on quality of care and outcomes for patients with obesity. Obes Rev. 2015.pmc.ncbi.nlm.nih.gov ↗
- Puhl RM. Weight Stigma and Barriers to Effective Obesity Care. Gastroenterol Clin North Am. 2023.uconnruddcenter.org ↗
- Ravussin, Smith & Ferrante. Physiology of Energy Expenditure in the Weight-Reduced State (Obesity 2021)pmc.ncbi.nlm.nih.gov ↗
- Ryan G, et al. Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes. Drug Des Devel Ther. 2008. (PMC2761191)pmc.ncbi.nlm.nih.gov ↗
- Sarwan, Daley & Rehman. Management of Weight Loss Plateau (StatPearls, NCBI Bookshelf 2024)ncbi.nlm.nih.gov ↗
- Solis-Herrera C, Kane MP, Triplitt C. SNAC as an Absorption Enhancer: The Oral Semaglutide Experience (Clinical Diabetes 2024;42(1):74; DOI 10.2337/cd22-0118)diabetesjournals.org ↗
- Toro-Tobon D, Singh Ospina N, Brito JP. Thyroid Cancer Risk with GLP-1 Receptor Agonists: Evidence, Knowledge Gaps, and the Path Forward. Thyroid. 2025. (Rodent-vs-human C-cell biology; synthesis of conflicting human data; boxed-warning context.)journals.sagepub.com ↗
- Voros C et al. GLP-1 Receptor Agonists in Reproductive Health: IVF Data, Ovarian Physiology & Mechanisms — Systematic Review (Int J Mol Sci 2026;27:759)pmc.ncbi.nlm.nih.gov ↗
- What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid (KFF, 2026) — Bridge extended through end of 2027 (originally Dec 31, 2026)kff.org ↗
Observational studies 29
Real-world associations — informative, but cannot prove cause.
- Aging Changes of the Superficial Fat Compartments of the Midface Over Time: An MRI Study. Dermatol Surg. 2020;46(12):1600–1605. (Midface fat compartments thin and shift with age.)pubmed.ncbi.nlm.nih.gov ↗
- Bezin J, et al. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care. 2023;46(2):384–390. (French nested case-control, 2,562 cases; all-thyroid aHR 1.58 [1.27–1.95]; medullary aHR 1.78 [1.04–3.05], 1–3 years' use.)diabetesjournals.org ↗
- Castaneda R, Hurtado-Andrade MD, et al. The role of menopause hormone therapy in modulating tirzepatide-associated weight loss in postmenopausal women with overweight or obesity: a retrospective cohort study. Lancet Obstet Gynaecol Womens Health. 2026. (N=120; ~35% more weight loss with hormone therapy; authors state it cannot show causation.)thelancet.com ↗
- Castellana E, Chiappetta MR. Exploring the Potential Link Between Tirzepatide and NAION: Evidence from FAERS and Google Trends. Hosp Pharm. 2026.journals.sagepub.com ↗
- Castellana E, Chiappetta MR. Exploring the Potential Link Between Tirzepatide and Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION): Evidence from FAERS and Google Trends. Hosp Pharm. 2026.pmc.ncbi.nlm.nih.gov ↗
- Cesta CE, Rotem R, Bateman BT, et al. Safety of GLP-1 Receptor Agonists and Other Second-Line Antidiabetics in Early Pregnancy. JAMA Intern Med. 2024;184(2):144–152. (51,826 pregnancies; periconceptional GLP-1 vs insulin, adjusted RR 0.95, 95% CI 0.72–1.26 for major malformations; 'initial reassurance,' still not recommended in pregnancy.)doi.org ↗
- Dai H, Li Y, Lee YA, et al. GLP-1 Receptor Agonists and Cancer Risk in Adults With Obesity. JAMA Oncol. 2025;11(10):1186–1193. (Target-trial emulation, 86,632 adults with obesity; overall cancer HR 0.83 [0.76–0.91]; endometrial 0.75; ovarian 0.53; meningioma 0.69; colorectal 0.88 NS; kidney 1.38 NS.)jamanetwork.com ↗
- Dao K et al. Use of GLP-1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on six Teratology Information Services. BMJ Open. 2024;14(4):e083550 (PMID 38663923).pubmed.ncbi.nlm.nih.gov ↗
- Fothergill E, et al. Persistent metabolic adaptation 6 years after 'The Biggest Loser' competition. Obesity (Silver Spring). 2016;24(8):1612-1619. PMID 27136388. (Resting metabolic rate remained suppressed six years after major weight loss — primary human evidence that metabolic adaptation persists long-term.)pubmed.ncbi.nlm.nih.gov ↗
- Fothergill E, et al. Persistent metabolic adaptation 6 years after 'The Biggest Loser' competition. Obesity. 2016;24(8):1612–1619. (n=14; resting metabolism −499 ± 207 kcal/day below predicted at 6 years; 41.0 ± 31.3 kg regained.)pmc.ncbi.nlm.nih.gov ↗
- Gasoyan H, et al. Real-world weight loss with semaglutide/tirzepatide (Cleveland Clinic EHR cohort, ~7,900 adults without diabetes): mean ~8.7% at 1 year; by adherence 3.6% (early discontinuers) / 6.8% / 11.9% (stayed on).ajmc.com ↗
- Gleason PP, et al. Real-world persistence and adherence to anti-obesity GLP-1 medications (2021 initiators, non-diabetic obesity, n=4,066). J Manag Care Spec Pharm. 2024;30(8):860-867. PMC11293763. 1-year persistence 32.3%, adherence 27.2%; persistence by product (semaglutide 47.1%, liraglutide 19.2%).pmc.ncbi.nlm.nih.gov ↗
- GLP-1 receptor agonist weight-loss genetics (GWAS of ~27,885 GLP-1 users). Nature. 2026. s41586-026-10330-z. GLP1R missense variant ≈ +0.76 kg loss per allele; genetics + clinical factors ≈ ~25% of response variance. Headline figures independently confirmed via The Pathologist; primary PDF access-gated at time of review.nature.com ↗
- Glucagon-Like Peptide 1 Receptor Agonists and Risk of Thyroid Cancer: An International Multisite Cohort Study. Thyroid. 2024/2025. PMID 39772758. (98,147 GLP-1 RA users vs 2,488,303 DPP-4i users, 6 countries; pooled HR 0.81 [0.59–1.12]; no short-term association.)pubmed.ncbi.nlm.nih.gov ↗
- Grauslund J, et al. Semaglutide and risk of nonarteritic anterior ischemic optic neuropathy — a nationwide Danish cohort. Int J Retina Vitreous. 2024.pmc.ncbi.nlm.nih.gov ↗
- Hathaway JT, et al. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. JAMA Ophthalmology. 2024.pubmed.ncbi.nlm.nih.gov ↗
- Lähteenvuo M, et al. Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder (Swedish nationwide cohort, 227,868 people). JAMA Psychiatry. 2025.jamanetwork.com ↗
- Le Roux CW et al. Comparative effectiveness of tirzepatide and semaglutide for obesity management in US clinical practice — 6-month retrospective cohort (J Endocrinol Invest 2026)pmc.ncbi.nlm.nih.gov ↗
- Marshall LZ, et al. Trends in 1-year persistence and adherence to high-potency weight-loss GLP-1s (Prime Therapeutics claims, n=33,607). J Manag Care Spec Pharm. 2026;32(3). PMC12948759. Persistence rising 33.2% (2021) → 60.9% (1H 2024); tirzepatide ~64.8%.pmc.ncbi.nlm.nih.gov ↗
- Monpellier VM et al. Body Contouring Surgery after Massive Weight Loss: Excess Skin & Body Satisfaction (Plast Reconstr Surg 2019;143:1353, PMID 30789477)pubmed.ncbi.nlm.nih.gov ↗
- Sami K et al. Image Analyzer Study of the Skin in Patients With Morbid Obesity and Massive Weight Loss (Eplasty 2015;15:e4, PMID 25671051)pmc.ncbi.nlm.nih.gov ↗
- Sehgal NKR, et al. Self-reported side effects of semaglutide and tirzepatide in online communities (analysis of 410,198 Reddit posts). Nature Health. 2026.nature.com ↗
- Semaglutide and accelerated sarcopenia in older adults with type 2 diabetes: 24-month retrospective cohort (n=220 semaglutide vs 212 controls, mean age ~72). Greater loss of appendicular skeletal muscle index (female −0.39, male −0.26 kg/m²), grip strength (24.5→22.9 kg female) and gait speed, dose-dependent; observational, cannot prove causation. PMC12235021.pmc.ncbi.nlm.nih.gov ↗
- Sen S, et al. Glucagon-Like Peptide-1 Receptor Agonist Use and Residual Gastric Content Before Anesthesia. JAMA Surgery. 2024.pmc.ncbi.nlm.nih.gov ↗
- Shu Y, He X, Wu P, et al. Gastrointestinal adverse events associated with semaglutide: a pharmacovigilance study based on the FDA Adverse Event Reporting System. Front Public Health. 2022;10:996179. (Dry mouth among 17 'new/unexpected' AEs not in the label; weak signal, ROR lower bound 1.63.)pmc.ncbi.nlm.nih.gov ↗
- Sodhi M et al. Risk of Gastrointestinal Adverse Events Associated With GLP-1 Receptor Agonists for Weight Loss. JAMA. 2023;330(18):1795–1797.doi.org ↗
- Sumithran P, et al. Long-Term Persistence of Hormonal Adaptations to Weight Loss. N Engl J Med. 2011;365:1597–1604. (n=50; ~13.5 kg loss; leptin/ghrelin/appetite still shifted toward hunger at 62 weeks.)pubmed.ncbi.nlm.nih.gov ↗
- Telogen Effluvium Associated With Weight Loss: A Single-Center Retrospective Studypmc.ncbi.nlm.nih.gov ↗
- Wang W, et al. Association of semaglutide with risk of suicidal ideation in a real-world cohort. Nature Medicine. 2024;30:168–176. (Semaglutide linked to 49–73% lower risk of incident/recurrent suicidal ideation vs comparators.)pubmed.ncbi.nlm.nih.gov ↗
Registries 3
Large real-world datasets.
- A Study of Orforglipron (LY3502970) in Adults With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1, NCT05869903)clinicaltrials.gov ↗
- Does Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity? — trial registration (NCT05895643), ClinicalTrials.govclinicaltrials.gov ↗
- TRANSCEND-T2D-1 trial registration (NCT06354660), ClinicalTrials.govclinicaltrials.gov ↗
Agency / news 32
Official FDA/EMA announcements and reporting.
- "Does the 'gelatin trick' work for weight loss? Dietitians explain." TODAY. (Used only to describe the viral trend: ~6 g protein, ~23 kcal per packet; protein-preload satiety — not an efficacy source.)today.com ↗
- AACE: GLP-1RA Microdosing Trend Continues Despite 'Anecdotal Evidence' (Oct 28, 2025)aace.com ↗
- AJMC — Retatrutide achieves up to 30.3% average weight loss in phase 3 TRIUMPH-1 (ADA 2026 coverage)ajmc.com ↗
- American College of Gastroenterology — Anti-Obesity Drugs Will Not be Covered by Medicare and Medicaid in 2026 (the CMS obesity reinterpretation was not finalized on April 4, 2025, so the statutory exclusion stands)gi.org ↗
- Busetto L, et al. Pooled analysis of semaglutide in adults ≥65 years (STEP 1/3/4/5/8/9), presented at the European Congress on Obesity (EASO) 2026 — reported via ScienceDaily. −15.4% vs −5.1% weight loss in ≥65; 358 of 4,523 participants were ≥65 (~90% aged 65–74); AE 89.1% vs 84.5%, serious AE 19.0% vs 12.7%; fractures and hypoglycemia <1% both groups.sciencedaily.com ↗
- Cleveland Clinic Health Essentials. "'Ozempic Babies': How GLP-1 Agonists Affect Fertility." (Clinician-authored patient education.)health.clevelandclinic.org ↗
- CVS Health — CVS Caremark delivers affordability and access to GLP-1 weight management medications with expanded coverage options (May 28, 2026 announcement: Zepbound returns as an additional preferred option Oct 1, 2026; Foundayo unblocked June 1, 2026)cvshealth.com ↗
- Eli Lilly — Retatrutide (triple agonist) delivered up to ~30% weight loss in the pivotal phase-3 TRIUMPH-1 trial (topline; not yet peer-reviewed). May 2026.prnewswire.com ↗
- Eli Lilly. Lilly's SURMOUNT-1 results published in the New England Journal of Medicine (press release). (Confirms SURMOUNT-1 endpoints: −16.0% to −22.5% at week 72; placebo −3.1%.)investor.lilly.com ↗
- Eli Lilly. Retatrutide delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1): 28.3% mean weight loss at the top dose at 80 weeks — company topline, May 21, 2026investor.lilly.com ↗
- FDA Approves First Medication for Obstructive Sleep Apnea (Zepbound, Dec 2024)fda.gov ↗
- FDA Approves First New Molecular Entity Under National Priority Voucher Program (FDA press announcement, 2026)fda.gov ↗
- FDA Approves First Treatment for Liver Scarring Due to Fatty Liver Disease (resmetirom/Rezdiffra, Mar 14, 2024)fda.gov ↗
- FDA Approves First Treatment to Reduce Risk of Serious Heart Problems in Adults with Obesity or Overweight (Wegovy, 2024)fda.gov ↗
- FDA approves Lilly's Foundayo (orforglipron), the oral GLP-1 pill (Apr 2026)prnewswire.com ↗
- FDA Approves New Medication for Chronic Weight Management (Zepbound, 2023)fda.gov ↗
- FDA approves Novo Nordisk's oral semaglutide 25 mg for weight management — company announcement (Dec 2025)prnewswire.com ↗
- FDA Approves Oral Wegovy on Positive OASIS Trial Results (approval December 22, 2025). Applied Clinical Trials.appliedclinicaltrialsonline.com ↗
- FDA approves Ozempic (semaglutide) to reduce the risk of worsening kidney disease and cardiovascular death in T2D with CKD (Novo Nordisk, January 2025)prnewswire.com ↗
- FDA Approves Treatment for Serious Liver Disease Known as 'MASH' (Wegovy, August 2025)fda.gov ↗
- HCPLive — TRIUMPH-1: Retatrutide Substantially Lowers Weight, BMI in Patients With Obesity or Overweight (ADA 2026 coverage; 2,339 adults; 28.3% at 12 mg vs 2.2% placebo at 80 wk; dysesthesia 5.1%/12.3%/12.5% vs 0.9%)hcplive.com ↗
- Healthline — "'Ozempic Teeth': GLP-1 Drugs May Cause Tooth Decay, Experts Say" (consumer coverage characterizing the viral term)healthline.com ↗
- IU Today — CVS Caremark changes coverage for weight loss drug (July 1, 2025 removal of Zepbound from the CVS Caremark commercial template formulary; Wegovy made preferred)today.iu.edu ↗
- Novo Nordisk — FDA approves oral Wegovy (oral semaglutide 25 mg) for weight management (OASIS program; ~16.6% mean loss when adherent). Dec 2025.novonordisk.com ↗
- Novo Nordisk / PR Newswire. Novo Nordisk files for FDA approval of CagriSema, the first once-weekly GLP-1 + amylin combination for weight management (Dec 2025).prnewswire.com ↗
- Novo Nordisk A/S. CagriSema demonstrated 23% weight loss in the open-label head-to-head REDEFINE 4 trial vs tirzepatide; the primary (non-inferiority) endpoint was not achieved (company announcement, Feb 23, 2026).globenewswire.com ↗
- NPR — Patients struggle to pay for obesity drugs as insurance coverage slips (April 22, 2026)npr.org ↗
- Pharmaceutical Technology: GLP-1RA microdosing trend continues despite 'anecdotal evidence'pharmaceutical-technology.com ↗
- Psychiatry Advisor / MPR — FDA Finds No Causal Link Between GLP-1 RAs and Suicidal Behavior (secondary report of the FDA meta-analysis: 91 trials, 107,910 patients; also the FDA Sentinel cohort of 1,161,983 GLP-1 vs 1,081,155 SGLT2i initiators)psychiatryadvisor.com ↗
- The Lancet — Expression of Concern regarding the Exenatide-PD3 trial (May 18, 2026): critical and major concerns over trial conduct and data integrity at the King's College Hospital site; investigation ongoing.thelancet.com ↗
- UT Southwestern Medical Center MedBlog — 'Surprise "Ozempic babies" underscore links between obesity and fertility' (clinician-authored institutional patient education).utswmed.org ↗
- Wegovy approved by FDA for noncirrhotic MASH with moderate-to-advanced fibrosis — announcement (Aug 15, 2025)prnewswire.com ↗
Preprints 1
Not yet peer-reviewed — flagged as such.
Other primary sources 28
Primary documents that don’t fit the above.
- Berberine modulates gut microbiota and metabolites in mice with glucose–lipid metabolic disturbance (AMPK activation, short-chain fatty acids, microbiota shifts). PMC. (Mouse study — preclinical mechanism, not human weight-loss proof.)pmc.ncbi.nlm.nih.gov ↗
- Cleveland Clinic — 'Ozempic Face': What It Is and How to Avoid It (patient education).health.clevelandclinic.org ↗
- Cleveland Clinic. Why Does My Weight Fluctuate So Much? (Daily fluctuation window ~5–6 lb — roughly 2–3 lb either direction — from water, sodium, hormones, glycogen and food; follow the trend over time.)health.clevelandclinic.org ↗
- Congressional Research Service — Medicare Coverage of GLP-1 Drugs (IF12758): statutory exclusion of drugs used for weight loss; Part D coverage only for an eligible diagnosis such as diabetes or (since 2024) cardiovascular risk reduction with Wegovycongress.gov ↗
- Conte C, Hall KD, Klein S. Is Weight Loss–Induced Muscle Mass Loss Clinically Relevant? JAMA. 2024 (Viewpoint).pubmed.ncbi.nlm.nih.gov ↗
- Drugs.com clinical Q&A aggregating the label hair-loss rates and telogen-effluvium framing, including the Canadian Wegovy product-monograph stratification by weight lost (5.3% with ≥20% loss vs 2.5% with <20%).drugs.com ↗
- Dushay J. “I'm a weight-loss doctor. Here's why I worry about GLP-1 microdoses” (STAT, opinion, May 29, 2026)statnews.com ↗
- EMA PRAC — NAION is a 'very rare' side effect of semaglutide (up to ~1 in 10,000). June 2025.ema.europa.eu ↗
- FDA Drug Safety Communication: FDA requests removal of the suicidal-behavior-and-ideation warning from GLP-1 receptor agonist labeling.fda.gov ↗
- FDA Drug Trials Snapshots: MOUNJARO (tirzepatide)fda.gov ↗
- FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List (FDA press announcement)fda.gov ↗
- FDA Warning Letter — GLP-1 Solution (715883, 09/09/2025)fda.gov ↗
- FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Lossfda.gov ↗
- Goldkorn A, Schwartz MB, Monterosso J. Views Among the General Public on New Anti-Obesity Medications and on the Perception of Obesity as a Failure of Willpower. Obes Sci Pract. 2025. (Two experiments; willpower-controllability rated 5.5/9; information about medications did not reduce willpower-blame.)pmc.ncbi.nlm.nih.gov ↗
- KFF — Medicaid Coverage of and Spending on GLP-1s (13 states covered GLP-1s for obesity as of Jan 2026, down from 16 in Oct 2025; gross Medicaid GLP-1 spending rose from ~$1B in 2019 to ~$9B in 2024)kff.org ↗
- KFF Quick Takes — What Medicare's Temporary Program Covering GLP-1s for Obesity Means for Beneficiaries (GLP-1 Bridge eligibility: BMI ≥35, or ≥27 with clinical criteria; the ~$50 copay does not count toward the Part D deductible or out-of-pocket cap)kff.org ↗
- MotherToBaby (OTIS) Fact Sheet — Semaglutide. (Reproductive-safety patient resource: stop ~2 months before attempting pregnancy; limited breastfeeding data.)mothertobaby.org ↗
- New study examines stigma toward women who lose weight using GLP-1 medications (Georgetown Lombardi press release, secondary coverage of Post et al. 2026).lombardi.georgetown.edu ↗
- New York State Dental Association. GLP-1s and Oral Health: What Your Patients Should Know. 2025-10-23. (Mechanism/anecdote framing; 'Ozempic tongue' described as patient-reported/unofficial.)nysdental.org ↗
- Newsome PN et al. Weight-dependent and -independent effects of semaglutide in MASH: secondary analysis of ESSENCE (AASLD, Nov 2025)pmc.ncbi.nlm.nih.gov ↗
- Novo Nordisk Medical — GLP-1 RA storage & stability (semaglutide product room-temperature windows)novonordiskmedical.com ↗
- Peterson-KFF Health System Tracker — Perspectives from employers on the costs and issues associated with covering GLP-1 agonists for weight loss. (Coverage tracks indication and formulary; most employer plans do not cover the obesity indication.)healthsystemtracker.org ↗
- Post S, Stock ML, Persky S. Social Perceptions of GLP-1-assisted Weight Loss in Black and White Women with Obesity. Stigma & Health. 2026. doi:10.1037/sah0000689. (n=402 U.S. women, ages 30–49; 'easy way out' belief predicted more fat phobia, blame, dislike, and social distance.)doi.org ↗
- Prado et al. Muscle matters: the effects of medically induced weight loss on skeletal muscle — commentary (Lancet Diabetes & Endocrinol, 2024)thelancet.com ↗
- Quimbayo-Cifuentes, et al. Weight Regain After GLP-1-Based Therapy Discontinuation: Failure, Physiology, or Follow-Up Gap. Cureus. 2026. Editorial / expert commentary. (Disease-recurrence framing: chronic relapsing condition, set-point re-emergence, fat-preferential regain concern, maintenance-oriented care.)pubmed.ncbi.nlm.nih.gov ↗
- Rohrich RJ, Pessa JE. The Fat Compartments of the Face: Anatomy and Clinical Implications for Cosmetic Surgery. Plast Reconstr Surg. 2007;119:2219–2227. (Facial fat is arranged in discrete compartments, not a uniform layer.)pubmed.ncbi.nlm.nih.gov ↗
- Telogen Effluvium — Cleveland Clinic patient referencemy.clevelandclinic.org ↗
- WHO safety signal: semaglutide medicines and non-arteritic anterior ischaemic optic neuropathy (NAION). World Health Organization. 27 June 2025.who.int ↗
Sources are cited nominatively for education. FDA drug-label claims link to the label via DailyMed or Drugs@FDA. This is educational content, not medical advice.